重组抗IgE抗体成功治疗变应性支气管肺曲霉病。
Successful treatment of allergic bronchopulmonary aspergillosis with recombinant anti-IgE antibody.
作者信息
van der Ent Cornelis K, Hoekstra Hans, Rijkers Ger T
机构信息
Department of Pediatric Respiratory Diseases, University Medical Center Utrecht, KH 01.419.0, PO Box 85090, 3508 AB Utrecht, The Netherlands.
出版信息
Thorax. 2007 Mar;62(3):276-7. doi: 10.1136/thx.2004.035519.
Abstract
Allergic bronchopulmonary aspergillosis (ABPA) can cause severe worsening of the respiratory condition in patients with cystic fibrosis. Treatment can result in steroid dependency and serious adverse events. A dramatic and rapid improvement of respiratory symptoms and lung function after a single dose of anti-IgE antibody (omalizumab) in a 12-year-old girl with cystic fibrosis and ABPA is described. This is the first report of this experimental treatment. It suggests an important role for IgE in the pathogenesis of ABPA and offers new therapeutic possibilities.
摘要
变应性支气管肺曲霉病（ABPA）可导致囊性纤维化患者的呼吸状况严重恶化。治疗可能导致类固醇依赖和严重不良事件。本文描述了一名患有囊性纤维化和ABPA的12岁女孩在单次注射抗IgE抗体（奥马珠单抗）后呼吸症状和肺功能出现显著且迅速的改善。这是关于这种实验性治疗的首次报告。它提示IgE在ABPA发病机制中起重要作用，并提供了新的治疗可能性。
相似文献
1
Successful treatment of allergic bronchopulmonary aspergillosis with recombinant anti-IgE antibody.重组抗IgE抗体成功治疗变应性支气管肺曲霉病。
Thorax. 2007 Mar;62(3):276-7. doi: 10.1136/thx.2004.035519.
2
Anti IgE antibody as treatment of allergic bronchopulmonary aspergillosis in a patient with cystic fibrosis.抗IgE抗体治疗一名囊性纤维化患者的变应性支气管肺曲霉病
Eur Rev Med Pharmacol Sci. 2014 Jul;18(13):1839-41.
3
Treatment of allergic bronchopulmonary aspergillosis (ABPA) in CF with anti-IgE antibody (omalizumab).使用抗IgE抗体（奥马珠单抗）治疗囊性纤维化（CF）中的过敏性支气管肺曲霉病（ABPA）。
Pediatr Pulmonol. 2008 Dec;43(12):1249-51. doi: 10.1002/ppul.20907.
4
Voriconazole in the treatment of allergic bronchopulmonary aspergillosis in cystic fibrosis.伏立康唑治疗囊性纤维化患者的变应性支气管肺曲霉病
Ir Med J. 2009 Jan;102(1):29.
5
Allergic bronchopulmonary aspergillosis in a patient with cystic fibrosis: diagnostic criteria when the IgE level is less than 500 IU/mL.一名囊性纤维化患者的变应性支气管肺曲霉病：IgE水平低于500 IU/mL时的诊断标准
Ann Allergy Asthma Immunol. 2005 Nov;95(5):488-93. doi: 10.1016/S1081-1206(10)61177-5.
6
Clinical efficacy and immunologic effects of omalizumab in allergic bronchopulmonary aspergillosis.奥马珠单抗治疗变应性支气管肺曲霉病的临床疗效和免疫效应
J Allergy Clin Immunol Pract. 2015 Mar-Apr;3(2):192-9. doi: 10.1016/j.jaip.2014.12.008. Epub 2015 Jan 29.
7
Effect of allergic bronchopulmonary aspergillosis on lung function in children with cystic fibrosis.变应性支气管肺曲霉病对囊性纤维化患儿肺功能的影响。
Am J Respir Crit Care Med. 2006 Dec 1;174(11):1211-20. doi: 10.1164/rccm.200603-423OC. Epub 2006 Sep 7.
8
Diagnosing allergic bronchopulmonary aspergillosis in children with cystic fibrosis.诊断患有囊性纤维化的儿童的变应性支气管肺曲霉病。
Paediatr Respir Rev. 2009 Mar;10(1):37-42. doi: 10.1016/j.prrv.2009.01.001.
9
Time course of antibody response to recombinant Aspergillus fumigatus antigens in cystic fibrosis with and without ABPA.患有和未患有变应性支气管肺曲霉病的囊性纤维化患者对重组烟曲霉抗原抗体反应的时间进程。
Pediatr Allergy Immunol. 2005 May;16(3):217-25. doi: 10.1111/j.1399-3038.2005.00262.x.
10
Potential role of the cellular allergen stimulation test (CAST) in diagnosis of allergic bronchopulmonary aspergillosis (ABPA) in cystic fibrosis.细胞变应原刺激试验（CAST）在囊性纤维化患者变应性支气管肺曲霉病（ABPA）诊断中的潜在作用
Pediatr Pulmonol. 2007 Apr;42(4):314-8. doi: 10.1002/ppul.20572.
引用本文的文献
1
Efficacy of Biologics in Patients with Allergic Bronchopulmonary Aspergillosis: A Systematic Review and Meta-Analysis.变应性支气管肺曲霉病患者使用生物制剂的疗效：系统评价和荟萃分析。
Lung. 2024 Aug;202(4):367-383. doi: 10.1007/s00408-024-00717-y. Epub 2024 Jun 19.
2
Rapid onset of effect of benralizumab in a severe eosinophilic and allergic asthma patient with allergic bronchopulmonary aspergillosis.贝那利珠单抗在一名患有变应性支气管肺曲霉病的重度嗜酸性粒细胞性和过敏性哮喘患者中起效迅速。
Respirol Case Rep. 2023 May 25;11(6):e01167. doi: 10.1002/rcr2.1167. eCollection 2023 Jun.
3
Biologic drugs in treating allergic bronchopulmonary aspergillosis in patients with cystic fibrosis: a systematic review.生物制剂治疗囊性纤维化患者变应性支气管肺曲霉病的系统评价。
Eur Respir Rev. 2022 Jul 27;31(165). doi: 10.1183/16000617.0011-2022. Print 2022 Sep 30.
4
An Overview of Off-Label Use of Humanized Monoclonal Antibodies in Paediatrics.人源化单克隆抗体在儿科领域的超说明书使用概述。
Medicina (Kaunas). 2022 Apr 29;58(5):625. doi: 10.3390/medicina58050625.
5
Use of Intravenous Pulse Steroids to Treat Allergic Bronchopulmonary Aspergillosis in a Non-Compliant Asthmatic Adolescent.在一名不依从治疗的哮喘青少年中使用静脉脉冲类固醇治疗变应性支气管肺曲霉病
Children (Basel). 2022 Feb 14;9(2):252. doi: 10.3390/children9020252.
6
Pediatric usage of Omalizumab: A promising one.奥马珠单抗在儿科的应用：前景广阔。
World Allergy Organ J. 2021 Dec 11;14(12):100614. doi: 10.1016/j.waojou.2021.100614. eCollection 2021 Dec.
7
Anti-IgE therapy for allergic bronchopulmonary aspergillosis in people with cystic fibrosis.抗 IgE 治疗囊性纤维化患者的变应性支气管肺曲霉病。
Cochrane Database Syst Rev. 2021 Sep 22;9(9):CD010288. doi: 10.1002/14651858.CD010288.pub5.
8
Current Approach in the Diagnosis and Management of Allergic Bronchopulmonary Aspergillosis in Children With Cystic Fibrosis.囊性纤维化患儿过敏性支气管肺曲霉菌病诊断与管理的当前方法
Front Pediatr. 2020 Oct 20;8:582964. doi: 10.3389/fped.2020.582964. eCollection 2020.
9
Successful Treatment with Benralizumab for Allergic Bronchopulmonary Aspergillosis That Developed after Disastrous Heavy Rainfall in Western Japan.成功使用贝那鲁肽治疗日本西部灾难性暴雨后发生的变应性支气管肺曲霉病。
Intern Med. 2021 May 1;60(9):1443-1450. doi: 10.2169/internalmedicine.6217-20. Epub 2020 Nov 16.
10
Differential response to biologics in a patient with severe asthma and ABPA: a role for dupilumab?重度哮喘和变应性支气管肺曲霉菌病患者对生物制剂的差异反应：度普利尤单抗起了什么作用？
Allergy Asthma Clin Immunol. 2020 Jun 26;16:55. doi: 10.1186/s13223-020-00454-w. eCollection 2020.
本文引用的文献
1
Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma.重组抗免疫球蛋白E抗体（奥马珠单抗）治疗重度过敏性哮喘的疗效与安全性。
Clin Exp Allergy. 2004 Apr;34(4):632-8. doi: 10.1111/j.1365-2222.2004.1916.x.
2
Pharmacodynamics of omalizumab: implications for optimised dosing strategies and clinical efficacy in the treatment of allergic asthma.奥马珠单抗的药效学：对优化给药策略及治疗过敏性哮喘临床疗效的意义
Curr Med Res Opin. 2003;19(6):491-8. doi: 10.1185/030079903125002171.
3
Allergic bronchopulmonary aspergillosis in cystic fibrosis--state of the art: Cystic Fibrosis Foundation Consensus Conference.囊性纤维化中的变应性支气管肺曲霉病——最新进展：囊性纤维化基金会共识会议
Clin Infect Dis. 2003 Oct 1;37 Suppl 3:S225-64. doi: 10.1086/376525.
4
Development of immune responses to Aspergillus at an early age in children with cystic fibrosis.囊性纤维化患儿幼年时期对曲霉菌免疫反应的发展。
Am J Respir Crit Care Med. 1994 Dec;150(6 Pt 1):1513-8. doi: 10.1164/ajrccm.150.6.7952609.
5
Specific serum immunopatterns in clinical phases of allergic bronchopulmonary aspergillosis.变应性支气管肺曲霉病临床阶段的特异性血清免疫模式。
J Allergy Clin Immunol. 1992 Oct;90(4 Pt 1):589-99. doi: 10.1016/0091-6749(92)90131-k.
Zotero 插件